You need to be signed in to add your comment.

The Questions We Should Be Able to Answer

An Introduction to Performance Measurement

By Michael Sidra


Since joining CCA about three years ago, I’ve been inspired by how, every day, you help cancer patients get the care they need.

You make treatment decisions, manage symptoms and complications, and deliver treatment with remarkable precision. You also listen, comfort, provide tools and equipment and drugs and hope. You analyze data, manage projects, coordinate and juggle many moving parts.

You keep the system moving.

But that’s not all.

I’ve also been inspired by the conversations I’ve had, with so many of you, about how we can do even better.

The questions that keeps popping up is; how do we know whether the system is truly delivering the best care possible?

AND

How do we make it better?

Most healthcare teams can answer questions about the performance of their own area. They can often describe wait-times, volumes, staffing pressures, and quality indicators within their area.

While individual clinic areas track their metrics effectively, connecting those data points across the full patient journey is our next major opportunity. Performance excellence depends on knowing where patients experience delays, where care breaks down, what outcomes are achieved, and how those outcomes can be improved across the entire patient’s journey.


A System for Patients

Yes, cancer care is complex, but the needs of patients are, for the most part, well known and consistent.

Patients need to be diagnosed quickly and receive effective treatment in a timely way. Each patient’s needs are unique, but at the end of the day, all patients need equitable access to support from the time they are diagnosed through to survivorship care, or palliative care.

A high-performing cancer system delivers those things reliably.


Our blind spots

Cancer care is one of the most data-rich areas in healthcare.

Still …

Many health systems (including ours) struggle to answer critical questions.

How long does it take a patient to move from first suspicion of cancer to treatment?

Where are delays occurring?

What are patients experiencing while they move through the health system?

Answering those questions can be challenging because the information needed to answer them sits in different systems, owned by different organizations, and reported through different governance structures.

Limits of current approaches to system performance measurement

Most healthcare organizations use a combination of quality improvement methods and performance reporting.

Both are essential.

Quality improvement methods such as Lean and Plan-Do-Study-Act cycles help teams identify problems and test solutions, locally. These methods can improve clinic flow, reduce delays, strengthen communication, and improve safety.

Performance scorecards provide leaders with a broader view of how programs are performing, especially when they look at trends over time.

Each approach serves an important purpose

But neither approach consistently provides a complete picture of patients’ trajectory.

Most measurement systems are designed around organizational structures. Patients experience care across those structures.


The seam between organizations

Many of the biggest risks to quality, safety, and timeliness occur during transitions.

For example, a patient with symptoms suggestive of cancer may begin in primary care. Then they move through diagnostic imaging, laboratory testing, specialist referral, and finally oncology consultation, and treatment.

Each step can function well on its own.

The overall trajectory can still be slow.

Because care spans multiple specialized teams and settings, building shared responsibility across these transitions helps us support patients more seamlessly. The same pattern appears elsewhere.

A patient receiving systemic therapy may develop serious treatment-related complications and present to an emergency department. Acute care clinicians manage the complication. Oncology teams adjust the treatment plan. The two events are directly connected from the patient's perspective. But these parts of the system are measured and governed separately.

The transition into survivorship presents another challenge. Patients often describe uncertainty about what comes next, who is responsible for ongoing follow-up, and where to seek help when new concerns emerge.

These issues are often described as handoff problems, coordination problems, or communication problems.

In many cases they are also measurement problems.

What is not measured is difficult to improve.


What performance science tells us

Performance measurement and performance excellence has evolved.

One of the most influential frameworks in healthcare comes from Avedis Donabedian, who described quality through structures, processes, and outcomes. High-performing systems measure all three because outcomes rarely improve without understanding the processes that produce them.¹

More recent frameworks, including the Triple Aim and Quadruple Aim, emphasize improving health outcomes, patient experience, and system performance simultaneously.²³

I’ve noticed that these ideas share one common principle.

Performance should be measured in ways that reflect how patients experience care.

For cancer programs, that means measuring outcomes that matter while also understanding the processes that influence those outcomes.

It means linking indicators together rather than viewing each one in isolation. It means recognizing that accountability sometimes extends beyond the boundary of a single organization.


The questions we should be able to answer

As we mature as a cancer system, the questions that guide performance improvement should become more sophisticated.

We should be able to answer questions like:

  • How long does the patient trajectory take from initial suspicion of cancer to treatment?

  • Where do delays occur across the system and how much do they contribute to overall wait times?

  • How are outcomes varying across populations, locations, and tumour streams?

These are not just research questions, they are operational priorities that help us deliver better care.

They help us understand whether the system is delivering the care patients need and where improvement efforts should be focused.

Patients do not experience cancer care at one organization at a time.

They experience a continuous trajectory.

When measurement follows organizational boundaries, system leaders have an incomplete view of that trajectory. When measurement follows the patient, opportunities for improvement become easier to identify.

Alberta's cancer system already possesses clinical expertise, commitment, and much of the data needed to support that work already exists.

The question is how do we bring those pieces together in ways that allow us to see the whole picture and create shared accountability for improvement.

In the next post, we will explore what that looks like in practice. We will examine several areas where cancer systems can begin measuring performance across the patient journey and discuss what other jurisdictions have shown is possible.


Michael is the Senior Program Lead of the Provincial Systems, Programs & Performance team in Cancer Care Alberta. He dedicates his career to improving patient outcomes and enhancing health system performance by optimizing processes and delivering innovative solutions to complex issues.


References:

  1. Donabedian A. The Quality of Care: How Can It Be Assessed? JAMA. 1988. https://jamanetwork.com/journals/jama/article-abstract/374139

  1. Institute for Healthcare Improvement. The IHI Triple Aim. https://www.ihi.org/initiatives/ihi-triple-aim

  1. Bodenheimer T, Sinsky C. From Triple to Quadruple Aim: Care of the Patient Requires Care of the Provider. Ann Fam Med. 2014. https://www.annfammed.org/content/12/6/573

  1. Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020. https://doi.org/10.1136/bmj.m4087

  1. Ontario Health. Cancer System Quality Index (CSQI). https://ontariohealth.ca/system/reporting/performance/csqi

  1. Basch E, Deal AM, Dueck AC, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of Clinical Oncology. 2016. https://pubmed.ncbi.nlm.nih.gov/26644527/

  1. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017. https://jamanetwork.com/journals/jama/fullarticle/2630810

  1. Jensen H, Tørring ML, Vedsted P. Prognostic consequences of implementing cancer patient pathways in Denmark. BMC Cancer. 2017. https://doi.org/10.1186/s12885-017-3623-8

<span class="translation_missing" title="translation missing: en-US.projects.blog_posts.show.load_comment_text">Load Comment Text</span>